DRG Epidemiology’s coverage of community-acquired bacterial pneumonia (CABP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the event rate of CABP for each country, as well as annualized event counts projected to the national population.

DRG Epidemiology’s CABP forecast will answer the following questions:

  • Of all people with CABP, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with CABP, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CABP over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of events for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following CABP subpopulations:

  • Diagnosed inpatient events by drug-treatment status.
  • Diagnosed outpatient events by drug-treatment status.

Table of contents

  • Community-Acquired Bacterial Pneumonia - Epidemiology - Mature Markets Data
    • Introduction
      • Key Findings
        • Overview
          • Event Rate of Community-Acquired Bacterial Pneumonia per 1,000 Among People of All Ages in 2018 and 2028
          • Relative Sizes of the Factors Contributing to the Trend in Events of Community-Acquired Bacterial Pneumonia over the Next Ten Years
      • Epidemiology Data
      • Methods
        • Diagnosed Inpatient and Outpatient Events
        • Diagnosed Inpatient Events
        • Diagnosed Outpatient Events
        • Percentage Drug-Treated
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Community-Acquired Bacterial Pneumonia
          • Studies Excluded from the Analysis of Community-Acquired Bacterial Pneumonia
        • Risk/Protective Factors
          • Risk/Protective Factors for Community-Acquired Bacterial Pneumonia
        • Bibliography

    Author(s): Fjoralba Kristo, MD, MPH

    Fjoralba Kristo has expertise in forecasting infectious diseases and chronic diseases in both the mature and global markets. She has extensive academic experience with quantitative and qualitative research methods.

    Prior to joining Decision Resources Group, she completed a postdoctoral fellowship at University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as Research Scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Fjoralba holds an MPH degree from Boston University School of Public Health, concentrating in Epidemiology and Biostatistics, and a medical degree from University of Medicine, Bucharest, Romania.